Analyst Price Target is $11.67
▲ +559.13% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cyclerion Therapeutics in the last 3 months. The average price target is $11.67, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 559.13% upside from the last price of $1.77.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Cyclerion Therapeutics. This rating has held steady since May 2020, when it changed from a Hold consensus rating.
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.